FDA Emergency Use Authorizations Put Regulatory Sandboxes Into Public Health Practice
Administrative agencies have long struggled with a basic problem: how to supervise technologies that move faster than conventional rulemaking. In that setting, regulatory sandboxes have emerged as a controlled experiment in governance, allowing developers and regulators to test new tools in real-world conditions while gathering information that standard approval pathways might miss. Until now, the term has been used almost entirely in connection with financial technology. This article argues that the concept reaches much farther, and it uses the US Food and Drug Administration’s Emergency Use Authorization program during COVID-19 as the clearest example.
The comparison is not superficial. FDA EUAs relied on real-world deployment as a source of evidence, rather than treating deployment as something to be delayed until every uncertainty had been eliminated. That approach is fundamentally different from the usual premarket model, in which the agency generally demands a more complete evidentiary package before a product enters broad use. During the pandemic, the pressure to act quickly collided with the need to preserve a meaningful regulatory standard. The EUA framework became a test case for whether administrative law can tolerate controlled flexibility without abandoning oversight.
Real-World Deployment as a Tool for Information Gathering
The central appeal of a sandbox is pragmatic. Instead of freezing innovation until regulators can collect ideal data, the agency allows limited use under supervision and learns from what happens next. In the FDA setting, that meant treatments and vaccines were introduced into urgent clinical use while evidence was still emerging. The agency was not simply opening the door to products; it was also using deployment itself as a mechanism for information gathering.
A regulatory sandbox depends on several features that the FDA’s COVID-19 EUAs clearly exhibited. The process is technologically flexible. It is shaped through close interaction with the developer. It is designed to generate shared knowledge rather than only to license a product. Those features make the EUA model resemble a sandbox far more than a conventional approval process. The result is a governance structure that is less static and more adaptive, especially when the underlying technology is novel and the social stakes are high.
The biological and clinical context matters here. Public health emergencies create pressure for speed because delay carries immediate human consequences. In that environment, a regulator cannot always wait for the perfect evidence package without accepting preventable harm from inaction. The EUA mechanism acknowledges that reality by permitting conditional use while evidence continues to accumulate. It does not erase uncertainty; it manages uncertainty under supervision.
Public Trust, Political Pressure, and the Limits of Flexibility
A one-sentence reality check: emergency flexibility can expand access, but it can also weaken confidence if standards appear improvised.
That tension ran through FDA’s pandemic response. EUAs were not only technical decisions about evidence and authorization. They also became symbols in a politically charged environment, where public trust in the agency could rise or fall depending on how consistently standards were applied. The more the agency relies on a sandbox-like model, the more it must explain why a temporary or conditional pathway still reflects serious regulatory judgment.
This is where public health differs from finance in important ways. A financial sandbox may affect markets, contracts, or consumer choice; a public health sandbox can affect infection control, vaccination uptake, treatment access, and confidence in medical institutions. The stakes are not abstract. They are distributed across patients, clinicians, and communities, often in settings where misinformation spreads quickly and regulatory ambiguity can have downstream consequences. For that reason, the use of sandbox logic in medicine cannot be separated from the social conditions under which the agency acts.
Why the EUA Model Fits the Sandbox Framework
FDA’s COVID-19 EUAs show how a sandbox can function in a public health setting without formally carrying that name. They were rooted in real-world deployment. They were responsive to technological change. They reflected close cooperation with developers. They also served a knowledge-producing role, helping the agency and the public learn more about products under urgent conditions. Those traits align closely with the article’s broader theory of regulatory sandboxes as an underrecognized feature of administrative governance.
The article also identifies an important boundary. Public health is often treated as exceptional subject matter in administrative law, and the pandemic was exceptional in scale and urgency. Those facts do not invalidate the sandbox theory; they complicate it. If an EUA process qualifies as a regulatory sandbox in such an extreme environment, the concept may be more durable than critics assume. At the same time, the pandemic setting makes it impossible to claim that every lesson from FDA can be transferred unchanged to other sectors. The framework may travel, but it will not travel intact.
A second one-sentence reality check: the more an agency learns through deployment, the more it must defend the standards that separate controlled experimentation from permissive drift.
What This Means for Administrative Governance of New Technologies
The practical implication is that regulators may already be using sandbox-like tools without labeling them that way. If so, the next step is not to celebrate the label but to identify the structures beneath it. Future work should determine whether regulatory sandboxes exist under the rubric developed here, which technologies they govern, and how they operate in practice. That includes asking how much agency oversight is enough, how developer input should be balanced against independent review, and when a temporary pathway becomes too unstable to support durable public confidence.
In public health, those questions carry added weight because the evidence base can shift while decisions are still being made. A sandbox model may be well suited to that problem, but only if the regulatory system preserves transparency, credible standards, and enough discipline to prevent emergency authority from becoming routine habit. The FDA’s pandemic EUAs suggest that real-world testing can be both a source of knowledge and a test of institutional legitimacy. The unresolved issue is not whether agencies can experiment; it is how much uncertainty a public health regulator can absorb before the experiment itself begins to define the standard.